Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Prothena Corporation plc - Ordinary Shares
(NQ:
PRTA
)
9.190
+0.140 (+1.55%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 9, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Prothena Corporation plc - Ordinary Shares
< Previous
1
2
3
Next >
Prothena Announces Board of Directors Update
December 12, 2025
From
Prothena Corporation plc
Via
Business Wire
Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025
November 19, 2025
From
Prothena Corporation plc
Via
Business Wire
Prothena Highlights Phase 2 Data for Coramitug (Formerly PRX004) Published in Circulation, Official Journal of AHA
November 11, 2025
From
Prothena Corporation plc
Via
Business Wire
Prothena Reports Third Quarter 2025 Financial Results and Business Highlights
November 06, 2025
From
Prothena Corporation plc
Via
Business Wire
Prothena to Report Third Quarter 2025 Financial Results on November 6
October 30, 2025
From
Prothena Corporation plc
Via
Business Wire
Prothena’s Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer’s Disease
October 01, 2025
From
Prothena Corporation plc
Via
Business Wire
Prothena to Participate in the Cantor Fitzgerald Global Healthcare Conference
August 28, 2025
From
Prothena Corporation plc
Via
Business Wire
Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program
August 27, 2025
From
Prothena Corporation plc
Via
Business Wire
Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy
August 06, 2025
From
Prothena Corporation plc
Via
Business Wire
Prothena Reports Second Quarter 2025 Financial Results and Business Highlights
August 04, 2025
From
Prothena Corporation plc
Via
Business Wire
Prothena to Report Second Quarter 2025 Financial Results on August 4
July 28, 2025
From
Prothena Corporation plc
Via
Business Wire
Prothena Announces Corporate Restructuring
June 18, 2025
From
Prothena Corporation plc
Via
Business Wire
Prothena’s Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease
June 16, 2025
From
Prothena Corporation plc
Via
Business Wire
Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint
May 23, 2025
From
Prothena Corporation plc
Via
Business Wire
Prothena Reports First Quarter 2025 Financial Results and Business Highlights
May 08, 2025
From
Prothena Corporation plc
Via
Business Wire
Prothena to Report First Quarter 2025 Financial Results on May 8
May 01, 2025
From
Prothena Corporation plc
Via
Business Wire
Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights
February 20, 2025
From
Prothena Corporation plc
Via
Business Wire
Prothena to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025
February 13, 2025
From
Prothena Corporation plc
Via
Business Wire
Prothena Announces Board of Directors Update
December 30, 2024
From
Prothena Corporation plc
Via
Business Wire
Roche’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson’s Disease
December 19, 2024
From
Prothena Corporation plc
Via
Business Wire
Prothena Reports Third Quarter 2024 Financial Results and Business Highlights
November 12, 2024
From
Prothena Corporation plc
Via
Business Wire
Prothena to Report Third Quarter 2024 Financial Results on November 12
November 05, 2024
From
Prothena Corporation plc
Via
Business Wire
Prothena Announces Leadership Team Updates
September 27, 2024
From
Prothena Corporation plc
Via
Business Wire
Prothena to Participate in Upcoming Healthcare Conferences
August 29, 2024
From
Prothena Corporation plc
Via
Business Wire
Prothena Reports Second Quarter 2024 Financial Results and Business Highlights
August 08, 2024
From
Prothena Corporation plc
Via
Business Wire
Prothena to Report Second Quarter 2024 Financial Results on August 8
August 01, 2024
From
Prothena Corporation plc
Via
Business Wire
Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration
May 28, 2024
From
Prothena Corporation plc
Via
Business Wire
Prothena Reports First Quarter 2024 Financial Results and Business Highlights
May 08, 2024
From
Prothena Corporation plc
Via
Business Wire
Prothena to Report First Quarter 2024 Financial Results on May 8
May 01, 2024
From
Prothena Corporation plc
Via
Business Wire
Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma
April 15, 2024
From
Prothena Corporation plc
Via
Business Wire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
